Definium Therapeutics Key Fundamental Indicators
| DFTX Stock | 16.25 0.78 4.58% |
As of the 6th of February, Definium Therapeutics shows the Downside Deviation of 3.79, mean deviation of 3.23, and Coefficient Of Variation of 1435.95. Definium Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Definium Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Definium Therapeutics' valuation are provided below:We have found one hundred thirteen available fundamental signals for Definium Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Definium Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 89.2 M in 2026. Enterprise Value is likely to drop to about 47.9 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Net Interest Income is likely to rise to about 11.2 M in 2026, whereas Depreciation And Amortization is likely to drop slightly above 450.6 K in 2026. Definium | Select Account or Indicator | Build AI portfolio with Definium Stock |
Definium Therapeutics Balance Sheet | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Definium Therapeutics Income Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Definium Therapeutics Cash Flow Statement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Ratios | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Definium Therapeutics Valuation Data | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Definium Fundamental Market Drivers
Definium Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Definium Therapeutics is extremely important. It helps to project a fair market value of Definium Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Definium Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Definium Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Definium Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Definium Therapeutics. Projected growth potential of Definium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Definium Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Definium Therapeutics is measured differently than its book value, which is the value of Definium that is recorded on the company's balance sheet. Investors also form their own opinion of Definium Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Definium Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Definium Therapeutics' market value can be influenced by many factors that don't directly affect Definium Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Definium Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Definium Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Definium Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Definium Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Definium Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Definium Therapeutics.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in Definium Therapeutics on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding Definium Therapeutics or generate 0.0% return on investment in Definium Therapeutics over 90 days. Definium Therapeutics is related to or competes with Boston Beer, Black Rock, Altigen Communications, Darden Restaurants, and Molson Coors. Definium Therapeutics is entity of United States More
Definium Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Definium Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Definium Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.79 | |||
| Information Ratio | 0.0588 | |||
| Maximum Drawdown | 16.61 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 7.13 |
Definium Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Definium Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Definium Therapeutics' standard deviation. In reality, there are many statistical measures that can use Definium Therapeutics historical prices to predict the future Definium Therapeutics' volatility.| Risk Adjusted Performance | 0.0605 | |||
| Jensen Alpha | 0.2739 | |||
| Total Risk Alpha | 0.0856 | |||
| Sortino Ratio | 0.0646 | |||
| Treynor Ratio | 1.72 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Definium Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Definium Therapeutics February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0605 | |||
| Market Risk Adjusted Performance | 1.73 | |||
| Mean Deviation | 3.23 | |||
| Semi Deviation | 3.64 | |||
| Downside Deviation | 3.79 | |||
| Coefficient Of Variation | 1435.95 | |||
| Standard Deviation | 4.16 | |||
| Variance | 17.29 | |||
| Information Ratio | 0.0588 | |||
| Jensen Alpha | 0.2739 | |||
| Total Risk Alpha | 0.0856 | |||
| Sortino Ratio | 0.0646 | |||
| Treynor Ratio | 1.72 | |||
| Maximum Drawdown | 16.61 | |||
| Value At Risk | (4.86) | |||
| Potential Upside | 7.13 | |||
| Downside Variance | 14.34 | |||
| Semi Variance | 13.22 | |||
| Expected Short fall | (3.73) | |||
| Skewness | 0.045 | |||
| Kurtosis | 1.27 |
Definium Therapeutics Backtested Returns
Definium Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Definium Therapeutics secures Sharpe Ratio (or Efficiency) of 0.16, which denotes the company had a 0.16 % return per unit of risk over the last 3 months. By reviewing Definium Therapeutics' technical indicators, you can evaluate if the expected return of 0.61% is justified by implied risk. Please utilize Definium Therapeutics' Downside Deviation of 3.79, mean deviation of 3.23, and Coefficient Of Variation of 1435.95 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Definium Therapeutics holds a performance score of 12. The firm shows a Beta (market volatility) of 0.16, which means not very significant fluctuations relative to the market. As returns on the market increase, Definium Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Definium Therapeutics is expected to be smaller as well. Please check Definium Therapeutics' total risk alpha, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether Definium Therapeutics' price patterns will revert.
Auto-correlation | 0.66 |
Good predictability
Definium Therapeutics has good predictability. Overlapping area represents the amount of predictability between Definium Therapeutics time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Definium Therapeutics price movement. The serial correlation of 0.66 indicates that around 66.0% of current Definium Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.66 | |
| Spearman Rank Test | 0.6 | |
| Residual Average | 0.0 | |
| Price Variance | 2.83 |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Definium Therapeutics has (79.13 Million) in Cash Flow From Operations. This is 115.01% lower than that of the Healthcare sector and 226.56% lower than that of the Biotechnology industry. The cash flow from operations for all United States stocks is 108.15% higher than that of the company.
Definium Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Definium Therapeutics's current stock value. Our valuation model uses many indicators to compare Definium Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Definium Therapeutics competition to find correlations between indicators driving Definium Therapeutics's intrinsic value. More Info.Definium Therapeutics is one of the top stocks in ebitda category among its peers. It also is one of the top stocks in net income category among its peers . Definium Therapeutics reported EBITDA of (95.28 Million) in 2025. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Definium Therapeutics' earnings, one of the primary drivers of an investment's value.Definium Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Definium Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Definium Therapeutics could also be used in its relative valuation, which is a method of valuing Definium Therapeutics by comparing valuation metrics of similar companies.Definium Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Definium Fundamentals
| EBITDA | (105.87 M) | ||||
| Net Income | (108.68 M) | ||||
| Total Debt | 21.85 M | ||||
| Cash Flow From Operations | (79.13 M) | ||||
| Number Of Employees | 74 | ||||
| Total Asset | 302.15 M | ||||
| Retained Earnings | (398.88 M) | ||||
| Working Capital | 242.77 M | ||||
| Net Asset | 302.15 M |
About Definium Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Definium Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Definium Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Definium Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Cost Of Revenue | 474.3 K | 450.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Definium Stock Analysis
When running Definium Therapeutics' price analysis, check to measure Definium Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Definium Therapeutics is operating at the current time. Most of Definium Therapeutics' value examination focuses on studying past and present price action to predict the probability of Definium Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Definium Therapeutics' price. Additionally, you may evaluate how the addition of Definium Therapeutics to your portfolios can decrease your overall portfolio volatility.